Envista (NYSE:NVST) Stock Price Up 3.7%

Envista Holdings Co. (NYSE:NVST - Get Free Report) rose 3.7% on Tuesday . The stock traded as high as $19.87 and last traded at $19.85. Approximately 1,561,901 shares traded hands during trading, a decline of 34% from the average daily volume of 2,360,976 shares. The stock had previously closed at $19.14.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. SVB Leerink assumed coverage on Envista in a report on Monday, February 26th. They set an "underperform" rating and a $19.00 price target on the stock. Jefferies Financial Group cut Envista from a "buy" rating to a "hold" rating and decreased their price target for the company from $30.00 to $23.00 in a report on Friday, February 9th. TheStreet cut Envista from a "c" rating to a "d+" rating in a report on Wednesday, February 7th. William Blair cut Envista from an "outperform" rating to a "market perform" rating in a report on Thursday, February 8th. Finally, Leerink Partnrs reaffirmed an "underperform" rating on shares of Envista in a report on Monday, February 26th. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $29.60.

Envista Stock Up 3.3 %

The company has a market cap of $3.40 billion, a P/E ratio of -32.43, a P/E/G ratio of 3.57 and a beta of 1.35. The company has a quick ratio of 1.90, a current ratio of 2.23 and a debt-to-equity ratio of 0.33. The business's 50 day moving average is $21.36 and its 200 day moving average is $23.03.

Envista (NYSE:NVST - Get Free Report) last issued its quarterly earnings data on Wednesday, February 7th. The company reported $0.29 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.04). The business had revenue of $645.60 million during the quarter, compared to the consensus estimate of $638.37 million. Envista had a positive return on equity of 6.31% and a negative net margin of 3.90%. The business's quarterly revenue was down 2.3% on a year-over-year basis. During the same period last year, the firm earned $0.52 EPS. As a group, equities analysts anticipate that Envista Holdings Co. will post 1.43 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Envista

Large investors have recently made changes to their positions in the business. Raymond James & Associates increased its position in shares of Envista by 6.1% in the 1st quarter. Raymond James & Associates now owns 56,493 shares of the company's stock valued at $2,752,000 after acquiring an additional 3,235 shares during the period. Bank of Montreal Can increased its position in shares of Envista by 13.9% in the 1st quarter. Bank of Montreal Can now owns 124,799 shares of the company's stock valued at $6,103,000 after acquiring an additional 15,228 shares during the period. Panagora Asset Management Inc. increased its position in shares of Envista by 8.1% in the 1st quarter. Panagora Asset Management Inc. now owns 6,543 shares of the company's stock valued at $319,000 after acquiring an additional 490 shares during the period. Great West Life Assurance Co. Can increased its position in shares of Envista by 8.6% in the 1st quarter. Great West Life Assurance Co. Can now owns 88,474 shares of the company's stock valued at $4,433,000 after acquiring an additional 7,020 shares during the period. Finally, Vontobel Holding Ltd. purchased a new stake in Envista in the first quarter valued at $390,000.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.